Join KHI

Publications

Barrier Type

All Clinical Trial Endpoints Clinical Trial Infrastructure Data Standards Education and Resources Patient Preferences Toolkits Annual Report Strategic Plan

Portfolio

All Devices Drugs Biologics Patient and Family Engagement
Submit a Project

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy

  • Clinical Trial Endpoints, Drugs

Fostering Innovation in Fluid Management

  • Clinical Trial Endpoints, Devices

Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access

  • Clinical Trial Endpoints, Devices

Recommended Clinical Trial End Points for Dialysis Catheters

  • Clinical Trial Endpoints, Devices

FDA Regulatory Perspectives for Studies on Hemodialysis Vascular Access

  • Clinical Trial Endpoints, Devices

Clinical Trial End Points for Hemodialysis Vascular Access: Background, Rationale, and Definitions

  • Clinical Trial Endpoints, Devices

Overcoming Barriers to Drug Development in Children with CKD : Clinical Journal of the American Society of Nephrology

  • Clinical Trial Endpoints, Drugs

Patient-Reported Outcomes in Hemodialysis Vascular Access: A Call to Action

  • Clinical Trial Endpoints, Devices

Developing Therapies for C3 Glomerulopathy Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group

  • Clinical Trial Endpoints, Drugs

End Point Considerations for Clinical Trials in Enteric Hyperoxaluria

  • Clinical Trial Endpoints, Drugs

End Points for Clinical Trials in Primary Hyperoxaluria

  • Clinical Trial Endpoints, Drugs

Primary Hyperoxaluria The Patient and Caregiver Perspective

  • Clinical Trial Endpoints, Drugs
Load More